Sign in
Taking peopleNo phase

Scandinavian Trial of Uncomplicated Aortic Dissection Therapy

Key facts

Who runs it
University of Aarhus
Where
Denmark, Finland, Iceland, Netherlands, Norway, and Sweden28 sites in 6 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
554 people, planned
Started
24 May 2023
Expected to end
31 Dec 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • TEVAR
Record updated
11 August 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • All subjects, aged 18 or greater at the time of informed consent, admitted or referred to the participating vascular surgery site with an uTBAD of less than four weeks duration

Who cannot take part

  • Subjects previously treated in their descending aorta, either open surgery or TEVAR
  • Subjects with an established connective tissue disease at the time of randomization, including but not limited to Marfans and Loeys-Dietz syndrome
  • Subjects with dementia
  • Subjects with a clinically estimated life expectancy < 2 years
  • Subjects with no signed informed consent
  • Subjects presenting with a complicated type B aortic dissection according to the above definition
  • Subjects with pre-existing thoracoabdominal aortic aneurysm
  • Subjects with other aortic pathology with an indication for intervention that requires TEVAR
  • Subjects with traumatic aortic dissections
  • Pregnant or nursing subjects
  • Subjects with current sepsis
  • Subjects currently participating in other clinical interventional trials

This trial has no sites in United States.

It has sites in 6 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The introduction of thoracic endovascular aortic repair (TEVAR) in 1994 has radically changed the treatment of thoracic aortic pathology, and TEVAR is now the recommended therapy for "complicated" TBADs and other thoracic aorta diseases. To date, the use of TEVAR in the treatment of "uncomplicated" dissections (uTBAD) is uncertain, although it is presumed that a prophylactic procedure can prevent later complex surgery and early death. Several analyses have found that TEVAR confers improved aortic remodeling and possibly survival, although these were underpowered for this specific outcome. In addition, there are several reports regarding the uncertain benefit or harm of this intervention in the vascular surgery community. Put another way, there is equipoise, and the need for robust evidence in the form of a randomized clinical trial has been clearly iterated by the European Society of Vascular Surgery.

Read full original descriptionShow less

This randomized, open-label, two-armed controlled study directly addresses this question of whether TEVAR alters 5-year survival among patients with an uTBAD. Patients will be randomized to either standard medical therapy (SMT) alone or TEVAR in addition to SMT. The primary outcome is 5-year survival, while secondary outcomes include aortic-related mortality, neurological events, quality of life, costs, re interventions and readmissions. in addition, subgroup analyses based on the extent of treatment.

Sample size calculations based on previous reports indicate the need to include approximately 554 patients. Patients will be recruited from multiple centres in Scandinavia. Based on the population (24 million) and incidence of uTBAD (approximately 480 per year), and depending on the total number of participating centres, a conservative estimate of two to three years is required for enrolment.

The 2 groups in the trial

  • Medical TherapyNo study treatment, for comparison

    Patients will be treated with standard medical therapy, i.e., antihypertensives, pulse-rate regulators, and pain medication.

  • Stent TherapyExisting treatment, for comparison

    Patients will be treated with both standard medical therapy, in addition to placement of a thoracic endovascular aortic repair stent graft.

    Treatment: TEVAR

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
11 August 2025